SignalChem Lifesciences (SLC) is committed to improving the care and outcome of patients by creating drugs to address unmet medical needs and that complement or replace existing treatments.

• Cancer Research article “Targeting Tumor Hypoxia: Suppression of Breast Tumor Growth and Metastasis by Novel Carbonic Anhydrase IX Inhibitors” Recognized as one of the Most Highly Cited in 2011.
• SignalChem Lifesciences’ Scientists Recognized in Journal of Medicinal Chemistry’s Highly Cited Article of 2011
• Attenuate the growth of primary breast tumors
• Interfering with pH regulation in tumours as a therapeutic strategy
• Scientists target enzyme and halt spread of deadly breast cancer tumours with novel drugs

• Targeting hypoxic tumor cells to overcome metastasis
• Targeting Tumor Hypoxia
• Antimetastatic activity in a model of breast cancer metastasis.
• ch-TOG and TACC3 in centrosome clustering in cancer cells
• Integrin-linked kinase is a functional Mn2+-dependent protein kinase